Recently, tazemetostat (EPZ6438), an inhibitor of the catalytic activity of EZH2, was approved for the treatment of advanced epithelioid sarcoma and follicular lymphoma13, and numerous clinical and preclinical trials are focused on combining EZH2 inhibitors with other drugs. This evidence concerns the gene EZH2 and epithelioid sarcoma.